Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
American Journal of Clinical Dermatology
Published in: American Journal of Clinical Dermatology 1/2018

01-02-2018 | Review Article

Drug-Induced Pyoderma Gangrenosum: A Review

Authors: Jane Y. Wang, Lars E. French, Neil H. Shear, Afkham Amiri, Afsaneh Alavi

Published in: American Journal of Clinical Dermatology | Issue 1/2018

Login to get access

Abstract

Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis that may be caused by an adverse drug reaction. We discuss the clinical presentation and outcomes of 52 cases of drug-induced PG reported to date in the literature. We conducted our literature search for case reports of drug-induced PG using keywords on PubMed and Medical Subject Heading (MeSH) terms on MEDLINE and EMBASE. To assess the probability that each case of PG was related to drug therapy, we used the Naranjo criteria. We identified 44 studies in the literature, with a total of 52 cases of drug-induced PG. The mean Naranjo score for cocaine-induced PG (n = 13) was 9.4, indicating a definite adverse drug reaction, while the mean Naranjo scores for isotretinoin (n = 5), propylthiouracil (n = 5), and sunitinib (n = 5) were 6.2, 6.8, and 7.4, respectively, indicating probable adverse drug reactions. Drugs should be considered as a possible triggering event whenever PG is diagnosed, and clinicians should particularly consider this in patients taking isotretinoin, propylthiouracil, or sunitinib, as well as in patients with a history of cocaine use.
Literature
1.
Crowson AN, Mihm MC Jr, Magro C. Pyoderma gangrenosum: a review. J Cutan Pathol. 2003;30(2):97–107.CrossRefPubMed
2.
Marzano AV, Damiani G, Ceccherini I, et al. Autoinflammation in pyoderma gangrenosum and its syndromic form (pyoderma gangrenosum, acne and suppurative hidradenitis). Br J Dermatol. 2016. doi:10.​1111/​bjd.​15226.
3.
Marzano AV, Fanoni D, Antiga E, et al. Expression of cytokines, chemokines and other effector molecules in two prototypic autoinflammatory skin diseases, pyoderma gangrenosum and Sweet’s syndrome. Clin Exp Immunol. 2014;178(1):48–56.CrossRefPubMedPubMedCentral
4.
Wollina U. Pyoderma gangrenosum—a review. Orphanet J Rare Dis. 2007;15(2):19.CrossRef
5.
Wu BC, Patel ED, Ortega-Loayza AG. Drug-induced pyoderma gangrenosum: a model to understand the pathogenesis of pyoderma gangrenosum. Br J Dermatol. 2016. doi:10.​1111/​bjd.​15193.
6.
Boulenger-Vazel A, Kupfer-Bessaguet I, Gouedard C, et al. Neutrophilic dermatosis associated with propylthiouracil-induced p-ANCA (p-antineutrophil cytoplasmic antibodies). Ann Dermatol Venereol. 2005;132(1):27–31.CrossRefPubMed
7.
Roche E, Martínez-Menchón T, Sánchez-Carazo JL, et al. Two cases of eruptive pyoderma gangrenosum associated with cocaine use. Actas Dermosifiliogr. 2008;99(9):727–30.CrossRefPubMed
8.
Yurci A, Guven K, Torun E, et al. Pyoderma gangrenosum and exacerbation of psoriasis resulting from pegylated interferon alpha and ribavirin treatment of chronic hepatitis C. Eur J Gastroenterol Hepatol. 2007;19(9):811–5.CrossRefPubMed
9.
Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–45.CrossRefPubMed
10.
Exner JH, Dahod S, Pochi PE. Pyogenic granuloma-like acne lesions during isotretinoin therapy. Arch Dermatol. 1983;119(10):808–11.CrossRefPubMed
11.
Dasanu CA, Bockorny B, Alexandrescu DT. Pyoderma gangrenosum due to lenalidomide use for multiple myeloma. J Oncol Pharm Pract. 2015;21(6):471–3.CrossRefPubMed
12.
Gangaram HB, Tan LP, Gan AT, et al. Pyoderma gangrenosum following treatment with isotretinoin. Br J Dermatol. 1997;136(4):636–7.CrossRefPubMed
13.
Sagara R, Kitami A, Nakada T, Iijima M. Adverse reactions to gefitinib (Iressa): revealing sycosis- and pyoderma gangrenosum-like lesions. Int J Dermatol. 2006;45(8):1002–3.CrossRefPubMed
14.
Sobieszczańska M, Tubek S, Kura I. Pyoderma gangrenosum-like skin changes after subcutaneous administration of low molecular weight heparin. Hum Vaccin Immunother. 2014;10(4):968–9.CrossRefPubMedPubMedCentral
15.
Su WP, Davis MD, Weenig RH, et al. Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria. Int J Dermatol. 2004;43(11):790–800.CrossRefPubMed
16.
17.
Dean SM, Zirwas M. A second case of sunitinib-associated pyoderma gangrenosum. J Clin Aesthet Dermatol. 2010;3(8):34–5.PubMedPubMedCentral
18.
19.
20.
Jiménez-Gallo D, Albarrán-Planelles C, Linares-Barrios M, et al. Pyoderma gangrenosum and Wegener granulomatosis-like syndrome induced by cocaine. Clin Exp Dermatol. 2013;38(8):878–82.CrossRefPubMed
21.
22.
Kowalzick L, Bertolini J, Baumann C, et al. Paradoxical reaction to etanercept: development of pyoderma gangraenosum during therapy of psoriasis arthritis. J Dtsch Dermatol Ges. 2013;11(5):447–9.PubMed
23.
Stichenwirth M, Riedl E, Pehamberger H, Tappeiner G. Pyoderma gangrenosum in a patient with seronegative rheumatoid arthritis during therapy with adalimumab: toxic effects of adalimumab or failure of adalimumab to prevent the onset of this phenomenon? Arch Dermatol. 2008;144(6):817–8.CrossRefPubMed
24.
Lewerin C, Mobacken H, Nilsson-Ehle H, Swolin B. Bullous pyoderma gangrenosum in a patient with myelodysplastic syndrome during granulocyte colony-stimulating factor therapy. Leuk Lymphoma. 1997;26(5–6):629–32.CrossRefPubMed
25.
Ross HJ, Moy LA, Kaplan R, Figlin RA. Bullous pyoderma gangrenosum after granulocyte colony-stimulating factor treatment. Cancer. 1991;68(2):441–3.CrossRefPubMed
26.
Freiman A, Brassard A. Pyoderma gangrenosum associated with isotretinoin therapy. J Am Acad Dermatol. 2006;55(5 Suppl):S107–8.CrossRefPubMed
27.
Hughes BR, Cunliffe WJ. Development of folliculitis and pyoderma gangrenosum in association with abdominal pain in a patient following treatment with isotretinoin. Br J Dermatol. 1990;122(5):683–7.CrossRefPubMed
28.
Tinoco MP, Tamler C, Maciel G, et al. Pyoderma gangrenosum following isotretinoin therapy for acne nodulocystic. Int J Dermatol. 2008;47(9):953–6.CrossRefPubMed
29.
Darben T, Savige J, Prentice R, et al. Pyoderma gangrenosum with secondary pyarthrosis following propylthiouracil. Australas J Dermatol. 1999;40(3):144–6.CrossRefPubMed
30.
Gungor K, Gonen S, Kisakol G, et al. ANCA positive propylthiouracil induced pyoderma gangrenosum. J Endocrinol Invest. 2006;29(6):575–6.CrossRefPubMed
31.
Hong SB, Lee MH. A case of propylthiouracil-induced pyoderma gangrenosum associated with antineutrophil cytoplasmic antibody. Dermatology. 2004;208(4):339–41.CrossRefPubMed
32.
33.
Miall FM, Harman K, Kennedy B, Dyer MJ. Pyoderma gangrenosum complicating pegylated granulocyte colony-stimulating factor in Hodgkin lymphoma. Br J Haematol. 2006;132(1):115–6.CrossRefPubMed
34.
Takagi S, Ohsaka A, Taguchi H, et al. Pyoderma gangrenosum following cytosine arabinoside, aclarubicin and granulocyte colony-stimulating factor combination therapy in myelodysplastic syndrome. Intern Med. 1998;37(3):316–9.CrossRefPubMed
35.
White LE, Villa MT, Petronic-Rosic V, et al. Pyoderma gangrenosum related to a new granulocyte colony-stimulating factor. Skinmed. 2006;5(2):96–8.CrossRefPubMed
36.
Mir-Bonafé JM, Blanco-Barrios S, Romo-Melgar A, et al. Photoletter to the editor: Localized pyoderma gangrenosum after interferon-alpha2b injections. J Dermatol Case Rep. 2012;6(3):98–9.CrossRefPubMedPubMedCentral
37.
Montoto S, Bosch F, Estrach T, et al. Pyoderma gangrenosum triggered by alpha2b-interferon in a patient with chronic granulocytic leukaemia. Leuk Lymphoma. 1998;30(1–2):199–202.CrossRefPubMed
38.
Park CW, Shin YS, Shin MJ, et al. Pyoderma gangrenosum and spinal epidural abscess after subcutaneous administration of recombinant human erythropoietin. Nephrol Dial Transplant. 1997;12:1506–8.CrossRefPubMed
39.
Nadauld LD, Miller MB, Srinivas S. Pyoderma gangrenosum with the use of sunitinib. J Clin Oncol. 2011;29(10):e266–7.CrossRefPubMed
40.
ten Freyhaus K, Homey B, Bieber T, Wilsmann-Theis D. Pyoderma gangrenosum: another cutaneous side-effect of sunitinib? Br J Dermatol. 2008;159(1):242–3.CrossRefPubMed
41.
Ueharaguchi Y, Kabashima K, Sasahashi M, et al. A case of pyoderma gangrenosum possibly associated with sunitinib treatment. Int J Dermatol. 2013;52(5):634–6.CrossRefPubMed
42.
Usui S, Otsuka A, Kaku Y, et al. Pyoderma gangrenosum of the penis possibly associated with pazopanib treatment. J Eur Acad Dermatol Venereol. 2016;30(7):1222–3.CrossRefPubMed
43.
Jaimes-López N, Molina V, Arroyave JE, et al. Developement of pyoderma gangraenosum during therapy with infliximab. J Dermatol Case Rep. 2009;3:20–3.CrossRefPubMedPubMedCentral
44.
Vandevyvere K, Luyten FP, Verschueren P, et al. Pyoderma gangrenosum developing during therapy with TNF-alpha antagonists in a patient with rheumatoid arthritis. Clin Rheumatol. 2007;26(12):2205–6.CrossRefPubMed
45.
Vestita M, Guida S, Mazzoccoli S, et al. Late paradoxical development of pyoderma gangrenosum in a psoriasis patient treated with infliximab. Eur J Dermatol. 2015;25(3):272–3.PubMed
46.
47.
Jeong HS, Layher H, Cao L, et al. Pyoderma gangrenosum (PG) associated with levamisole-adulterated cocaine: clinical, serologic, and histopathologic findings in a cohort of patients. J Am Acad Dermatol. 2016;74(5):892–8.CrossRefPubMed
48.
Keith PJ, Joyce JC, Wilson BD. Pyoderma gangrenosum: a possible cutaneous complication of levamisole-tainted cocaine abuse. Int J Dermatol. 2015;54(9):1075–7.CrossRefPubMed
49.
Tseng E, Alhusayen R, Sade S, et al. Pyoderma gangrenosum secondary to azacitidine in myelodysplastic syndrome. Br J Haematol. 2015;169(4):461.CrossRefPubMed
50.
51.
Rudolph BM, Staib F, Von Stebut E, et al. Neutrophilic disease of the skin and intestines after ipilimumab treatment for malignant melanoma—simultaneous occurrence of pyoderma gangrenosum and colitis. Eur J Dermatol. 2014;24(2):268–9.PubMed
Metadata
Title
Drug-Induced Pyoderma Gangrenosum: A Review
Authors
Jane Y. Wang
Lars E. French
Neil H. Shear
Afkham Amiri
Afsaneh Alavi
Publication date
01-02-2018
Publisher
Springer International Publishing
Published in
American Journal of Clinical Dermatology / Issue 1/2018
Print ISSN: 1175-0561
Electronic ISSN: 1179-1888
DOI
https://doi.org/10.1007/s40257-017-0308-7

Other articles of this Issue 1/2018

American Journal of Clinical Dermatology 1/2018 Go to the issue

Current Opinion

Choosing First-Line Biologic Treatment for Moderate-to-Severe Psoriasis: What Does the Evidence Say?

short communication

Evaluation of the Relationship between Alopecia Areata and Viral Antigen Exposure

Systematic Review

Systematic Review of Diagnostic Criteria Used in Atopic Dermatitis Randomized Controlled Trials

Research letter

Adult Atopic Dermatitis is Associated with Increased Aortic Stiffness

Review Article

Inherited Nonsyndromic Ichthyoses: An Update on Pathophysiology, Diagnosis and Treatment

Review Article

Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis